📊 LIXT Key Takeaways
Is Lixte Biotechnology Holdings, Inc.. (LIXT) a Good Investment?
LIXTE is a pre-revenue biotech company with minimal commercial traction ($200K revenue) and massive operating losses ($5.1M). Despite adequate liquidity, the company is burning $3.1M annually with only ~1.6 years of cash runway, leaving no margin for failure in drug development.
Fundamentals indicate a pre‑commercial biotech with minimal revenue and extremely negative margins, ROE, and ROA. Liquidity is solid and the balance sheet is debt‑free, but the current cash burn implies a limited runway and likely need for external financing. Until operating losses narrow materially or recurring revenue emerges, downside risk from dilution and execution remains high.
Why Buy Lixte Biotechnology Holdings, Inc.. Stock? LIXT Key Strengths
- Strong current ratio of 3.88x provides near-term liquidity buffer
- Zero long-term debt eliminates refinancing risk
- Positive stockholders equity of $9.7M provides balance sheet foundation
- Debt-free balance sheet
- Strong liquidity (current ratio ~3.9x)
- Positive equity relative to low liabilities
LIXT Stock Risks: Lixte Biotechnology Holdings, Inc.. Investment Risks
- Extreme cash burn ($3.1M/year) relative to cash reserves ($5.1M) creates imminent funding deadline
- Revenue near zero ($200K) with no evidence of commercialization pathway
- Operating margin of -2553.8% and net loss of $6.1M indicate company is in R&D phase with no near-term profitability
- Limited runway (~18-20 months) before forced dilutive financing or shutdown
- Zero insider buying in last 90 days suggests lack of confidence from management
- Sustained operating losses with minimal revenue base
- Cash burn likely necessitating dilutive financing
- Execution/clinical milestone risk impacting funding and timing
Key Metrics to Watch
- Cash runway depletion rate and burn trajectory
- Clinical trial progress and regulatory milestones for pipeline candidates
- Revenue growth rate and path to commercialization
- Secured financing or equity raise announcements
- Operating cash flow trend and quarterly burn rate changes
- Operating cash burn (OCF)
- Cash and equivalents / runway months
Lixte Biotechnology Holdings, Inc.. (LIXT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.88x current ratio provides a solid financial cushion.
LIXT Profit Margin, ROE & Profitability Analysis
LIXT vs Healthcare Sector: How Lixte Biotechnology Holdings, Inc.. Compares
How Lixte Biotechnology Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lixte Biotechnology Holdings, Inc.. Stock Overvalued? LIXT Valuation Analysis 2026
Based on fundamental analysis, Lixte Biotechnology Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lixte Biotechnology Holdings, Inc.. Balance Sheet: LIXT Debt, Cash & Liquidity
LIXT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lixte Biotechnology Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.59 indicates the company is currently unprofitable.
LIXT Revenue Growth, EPS Growth & YoY Performance
LIXT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2013 | N/A | -$16.1K | N/A |
| Q2 2013 | N/A | -$16.1K | N/A |
| Q1 2013 | N/A | -$16.1K | N/A |
| Q3 2012 | N/A | -$16.1K | N/A |
| Q2 2012 | N/A | -$16.1K | N/A |
| Q1 2012 | N/A | -$16.1K | N/A |
| Q3 2011 | N/A | -$16.1K | N/A |
| Q2 2011 | N/A | -$16.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lixte Biotechnology Holdings, Inc.. Dividends, Buybacks & Capital Allocation
LIXT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lixte Biotechnology Holdings, Inc.. (CIK: 0001335105)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIXT
What is the AI rating for LIXT?
Lixte Biotechnology Holdings, Inc.. (LIXT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIXT's key strengths?
Claude: Strong current ratio of 3.88x provides near-term liquidity buffer. Zero long-term debt eliminates refinancing risk. ChatGPT: Debt-free balance sheet. Strong liquidity (current ratio ~3.9x).
What are the risks of investing in LIXT?
Claude: Extreme cash burn ($3.1M/year) relative to cash reserves ($5.1M) creates imminent funding deadline. Revenue near zero ($200K) with no evidence of commercialization pathway. ChatGPT: Sustained operating losses with minimal revenue base. Cash burn likely necessitating dilutive financing.
What is LIXT's revenue and growth?
Lixte Biotechnology Holdings, Inc.. reported revenue of $200.0K.
Does LIXT pay dividends?
Lixte Biotechnology Holdings, Inc.. does not currently pay dividends.
Where can I find LIXT SEC filings?
Official SEC filings for Lixte Biotechnology Holdings, Inc.. (CIK: 0001335105) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIXT's EPS?
Lixte Biotechnology Holdings, Inc.. has a diluted EPS of $-1.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LIXT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lixte Biotechnology Holdings, Inc.. has a SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LIXT stock overvalued or undervalued?
Valuation metrics for LIXT: ROE of -62.9% (sector avg: 15%), net margin of -3,039.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LIXT stock in 2026?
Our dual AI analysis gives Lixte Biotechnology Holdings, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIXT's free cash flow?
Lixte Biotechnology Holdings, Inc..'s operating cash flow is $-3.1M, with capital expenditures of N/A. FCF margin is -1,535.3%.
How does LIXT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,039.3% (avg: 12%), ROE -62.9% (avg: 15%), current ratio 3.88 (avg: 2).